QNCX

Quince Therapeutics, Inc.

QNCX · CIK 1662774 · Annual (10-K) · Last 6 years

Financial Trends

Revenue
20192024
Net Income−$57M
20192024
Operating CF−$32M
20192024
Free Cash Flow−$32M
20192024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕
Revenue——————
Cost of Revenue——————
Gross Profit——————
R&D Expense$0.0B$0.0B$0.0B$0.1B$0.1B$0.0B
SG&A Expense——————
Operating Income$-0.1B$-0.0B$-0.1B$-0.1B$-0.1B$-0.0B
Net Income$-0.1B$-0.0B$-0.1B$-0.1B$-0.1B$-0.0B
EPS (Basic)$-1.31$-0.84$-1.54———
EPS (Diluted)$-1.31$-0.84$-1.54———

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕
Total Assets$0.1B$0.2B$0.1B$0.1B$0.2B$0.1B
Current Assets$0.0B$0.1B$0.1B$0.1B$0.1B$0.1B
Cash & Equivalents—————$0.1B
Total Liabilities$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.0B$0.1B$0.1B$0.1B$0.2B$0.1B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕
Operating Cash Flow$-0.0B$-0.0B$-0.0B$-0.1B$-0.1B$-0.0B
Investing Cash Flow$0.0B$-0.0B$0.0B$0.1B$-0.1B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$-0.0B$0.0B$0.0B$0.0B$0.1B$0.1B
← Companies